# BARINTHUS BIOTHERAPEUTICS PLC · Edgar & Edgarette company card

> Barinthus Biotherapeutics saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 75.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1828185 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/1828185) · [JSON](https://www.pops4.com/boards/company/1828185.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -454.1%) |
| Net margin | -Infinity% |
| Operating cash flow | −$48M |
| Capital spending | $37,000 |
| Free cash flow | −$48M |
| Cash | $70M |
| Long-term debt | — |
| Total assets | $98M |
| Total equity | $74M |
| Equity ÷ assets | 75.6% |
| Return on equity | -89.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.14 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from -454.1%. Soundness: equity 75.6% of assets, return on equity -89.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

Range logged 2026-09-20, receipt 07daee9dcd499e4e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 4, latest 2026-09-09 ([filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926106183/0001104659-26-106183-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-04-22 ([filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/0001104659-26-046861-index.htm))

## Recent filings

- 8-K · filed 2026-09-09 · 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926106183/0001104659-26-106183-index.htm)
- 8-K · filed 2026-09-01 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926104368/0001104659-26-104368-index.htm)
- 8-K · filed 2026-08-25 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/0001104659-26-100470-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/0001628280-26-053940-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000162828026053933/0001628280-26-053933-index.htm)
- 8-K · filed 2026-07-02 · 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/0001104659-26-080308-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001828185.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1828185

## Cite

POPS4, Edgar & Edgarette: BARINTHUS BIOTHERAPEUTICS PLC company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/1828185. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.